Earnings Call Summary | Paragon 28(FNA.US) Q1 2024 Earnings Conference
Earnings Call Summary | Paragon 28(FNA.US) Q1 2024 Earnings Conference
The following is a summary of the Paragon 28, Inc. (FNA) Q1 2024 Earnings Call Transcript:
以下是百麗宮28公司（FNA）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Paragon 28 globally achieved a Q1 2024 revenue of $61.1 million, an increase of 17.4%.
US business saw net revenue of $51.1 million in Q1, a 13.5% increase, with contributions from the increase in producing sales rep roster.
International net revenue for Q1 was $10 million, indicating a 42.2% reported growth.
Gross profit margin for Q1 was 80%, a decrease from 82.9% in Q1 2023 due to higher supplier prices and product/geographic mix shift.
Q1 2024 saw an increase in Selling, general, and administrative expenses, reaching $54.2 million, a rise of 23.7% from Q1 2023.
The company reported an increased adjusted EBITDA loss of $5.5 million for Q1 2024.
Operating cash flow was negative $11 million in Q1 2024 compared to negative $5 million in Q1 2023.
Paragon ended Q1 2024 with a total liquidity of $58 million in cash and $50 million available through a credit facility.
2024 net revenue guidance is reaffirmed at $249 million to $259 million.
百麗宮28全球在2024年第一季度實現了6,110萬美元的收入，增長了17.4％。
美國業務在第一季度淨收入爲5,110萬美元，增長13.5％，這要歸因於生產銷售代表名單的增加。
第一季度的國際淨收入爲1000萬美元，表明報告的增長率爲42.2％。
由於供應商價格上漲和產品/地域結構的變化，第一季度的毛利率爲80％，低於2023年第一季度的82.9％。
2024年第一季度的銷售、一般和管理費用有所增加，達到5,420萬美元，較2023年第一季度增長23.7％。
該公司報告稱，2024年第一季度調整後的息稅折舊攤銷前利潤虧損增加了550萬美元。
2024年第一季度的運營現金流爲負1,100萬美元，而2023年第一季度的運營現金流爲負500萬美元。
截至2024年第一季度，Paragon的總流動性爲5800萬澳元現金，5000萬美元可通過信貸額度獲得。
2024年的淨收入預期爲2.49億美元至2.59億美元。
Business Progress:
業務進展：
Record six new product launches and a limited market release in Q1 targeted high-growth Foot and Ankle segments.
Investment in product development continued, adding 6% to the US producing sales rep roster.
Significant international market expansions were made, particularly in the United Kingdom and Australia.
Over 25 active projects in pipeline, with several aligned with Smart28.
Reiteration of commitment to operating leverage and cost management while also investing in commercial and educational opportunities.
Expectation of OpEx reduction as a percentage of revenue in future quarters as revenue increases and previous operational expense investments are leveraged.
Successful launching of new products in the bunion market, like MIS, bunion portfolio, and FJ 2000, which are surpassing expectations.
Continuation of investment in innovation and technology with a consistent percentage of revenue on R&D planned for the future.
Geographic expansion plans underway including an increase in the US salesforce and broader international expansion.
Full product launch planned in the coming months for the Lapidus clamp, currently in limited release.
第一季度創紀錄的六款新產品發佈和限量市場發佈的目標是高增長的足部和腳踝細分市場。
對產品開發的投資仍在繼續，美國生產銷售代表名單增加了6％。
國際市場進行了重大擴張，特別是在英國和澳大利亞。
超過25個活躍的項目正在籌備中，其中一些項目與Smart28保持一致。
重申對運營槓桿和成本管理的承諾，同時也投資於商業和教育機會。
隨着收入的增加和先前的運營費用投資的槓桿作用，預計未來幾個季度運營支出佔收入的百分比將減少。
成功在拇囊炎市場上推出了超出預期的新產品，例如MIS、拇囊炎產品組合和FJ 2000。
繼續投資於創新和技術，並計劃在未來保持穩定的研發收入百分比。
地域擴張計劃正在進行中，包括增加美國銷售隊伍和更廣泛的國際擴張。
Lapidus夾具計劃在未來幾個月內全面上市，目前爲限量發行。
More details: Paragon 28 IR
更多詳情： Paragon 28 紅外線
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。